| 0.5942 -0.009 (-1.54%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.86 |
1-year : | 0.97 |
| Resists | First : | 0.74 |
Second : | 0.83 |
| Pivot price | 0.65 |
|||
| Supports | First : | 0.59 |
Second : | 0.49 |
| MAs | MA(5) : | 0.6 |
MA(20) : | 0.68 |
| MA(100) : | 2.41 |
MA(250) : | 2.25 |
|
| MACD | MACD : | -0.3  |
Signal : | -0.3 |
| %K %D | K(14,3) : | 3.5 |
D(3) : | 5.1 |
| RSI | RSI(14): 21.5 |
|||
| 52-week | High : | 5.82 | Low : | 0.36 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ELEV ] has closed above bottom band by 25.6%. Bollinger Bands are 77.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.62 - 0.62 | 0.62 - 0.62 |
| Low: | 0.59 - 0.59 | 0.59 - 0.59 |
| Close: | 0.59 - 0.59 | 0.59 - 0.6 |
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Sun, 15 Sep 2024
JMP Securities Initiates Coverage of Elevation Oncology (ELEV) with Market Outperform Recommendation - MSN
Tue, 03 Sep 2024
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference - Kilgore News Herald
Tue, 06 Aug 2024
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday? - Benzinga
Tue, 06 Aug 2024
Elevation Oncology: Proving That No One Knows How To Interpret Early-Stage Clinical Results - Seeking Alpha
Tue, 06 Aug 2024
Elevation Oncology stock falls on trial data (NASDAQ:ELEV) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 59 (M) |
| Shares Float | 38 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 104.5 (%) |
| Shares Short | 6,570 (K) |
| Shares Short P.Month | 6,680 (K) |
| EPS | -0.69 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.1 % |
| Return on Equity (ttm) | -51.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.68 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -43 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.88 |
| PEG Ratio | 0 |
| Price to Book value | 0.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|